Erin Currie

Erin Currie

Senior Associate

Erin is an associate in the Intellectual Property Litigation team in London.

She has gained experience working on contentious intellectual property matters, with a particular focus on patent litigation in the life sciences sector.

Erin has a BSc in Cell & Molecular Biology and has worked in biomedical research in Canada and the UK. At the University of British Columbia her work focussed on specialised cells in the olfactory system and their ability to stimulate neuronal regeneration following damage to the nervous system; her focus shifted to the regulation of haematopoietic stem cells in normal development and leukaemia at Cancer Research UK in London.

Her recent work includes acting for Eli Lilly in patent revocation proceedings relating to the dosage regimen of its blockbuster tadalafil product in first instance and appeal proceedings. She has subsequently assisted in co-ordinating multi-jurisdictional European litigation alongside completing a Postgraduate Diploma in Intellectual Property Law and Practice at the University of Oxford.

Published Work

  • United Kingdom - Life Sciences, Getting the Deal Through, 2015
  • Different motile behaviours of human hematopoietic stem versus progenitor cells at the osteoblastic niche, Stem Cell Reports, 2015
  • APOBEC3A is implicated in a novel class of G-to-A mRNA editing in WT1 transcripts, PLoS One, 2015
  • CD34(-) cells at the apex of the human hematopoietic stem cell hierarchy have distinctive cellular and molecular signatures, Cell Stem Cell, 2013
A&O Shearman was formed on May 1, 2024 by the combination of Shearman & Sterling LLP and Allen & Overy LLP and their respective affiliates (the legacy firms). Any matters referred to above may include matters undertaken by one or more of the legacy firms rather than A&O Shearman.